Cybin Inc. to Present at H.C. Wainwright Global Investment Conference
Cybin Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its late-stage neuropsychiatry developments including breakthrough therapy-designated treatments for major depressive disorder and generalized anxiety disorder.
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced that Chief Business Officer George Tziras will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 11:00 a.m. ET. This presentation provides investors and stakeholders with insights into the company's progress in developing next-generation mental health treatments.
The conference appearance comes at a critical juncture for Cybin, which is advancing multiple late-stage clinical programs targeting significant unmet needs in mental healthcare. The company's CYB003, a proprietary deuterated psilocin analog, is currently in Phase 3 studies for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation accelerates the development and review process for drugs that demonstrate substantial improvement over existing therapies.
Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 studies for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, positioning itself at the forefront of novel psychiatric treatment development. Investors can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN.
The participation in this prestigious investment conference underscores the growing importance of innovative mental health treatments in the pharmaceutical landscape. With mental health conditions affecting millions worldwide and existing treatments often providing inadequate relief, Cybin's approach represents a significant shift in therapeutic options. The company's operational presence across Canada, the United States, the United Kingdom, and Ireland demonstrates its global commitment to addressing mental health challenges through scientific innovation and clinical development.